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Congenital myopathies (CMs) are a heterogeneous group of inherited muscle disor-
ders characterized by muscle weakness at birth, while limb-girdle muscular dystro-
phies (LGMD) have a later onset and slower disease progression. Thus, detailed
clinical phenotyping of genetically defined disease entities are required for the full
understanding of genotype–phenotype correlations. A recently defined myopathic
genetic disease entity is caused by bi-allelic variants in a gene coding for pyridine
nucleotide-disulfide oxidoreductase domain 1 (PYROXD1) with unknown substrates.
Here, we present three patients from two consanguineous Turkish families with mild
LGMD, facial weakness, normal CK levels, and slow progress. Genomic analyses rev-
ealed a homozygous known pathogenic missense variant (c.464A>G, p.Asn155Ser) in
family 1 with two affected females. In the affected male of family 2, we found this
variant in a compound heterozygous state together with a novel frameshift variant
(c.329_332delTCTG, p.Leu112Valfs*8), which is the second frameshift variant known
so far in PYROXD1. We have been able to define a large homozygous region in family
1 sharing a common haplotype with family 2 in the critical region. Our data suggest
that c.464A>G is a Turkish founder mutation. To gain deeper insights, we performed
a systematic review of all published PYROXD1-related myopathy cases. Our analysis
showed that the c.464A > G variant was found in 87% (20/23) of the patients and
that it may cause either a childhood- or adult-onset phenotype, irrespective of its
presence in a homozygous or compound heterozygous state. Interestingly, only four
patients had elevated CK levels (up to 1000 U/L), and cardiac involvement was found
in few compound heterozygous cases.
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1 | INTRODUCTION
The congenital myopathies (CMs) are a heterogeneous group of rare
hereditary muscle diseases manifesting with hypotonia and muscle weak-
ness pre- or perinatally and are characterized histopathologically by dis-
tinctive structural lesions within the skeletal muscle (Walton &
Nattrass, 1954). CMs have been classified into five subgroups based on
the predominant structural pathological hallmarks present on skeletal mus-
cle biopsies: core myopathies, nemaline myopathies, centronuclear myopa-
thies, congenital fiber-type disproportion myopathy, and myosin storage
myopathy (Claeys, 2020; Scoto et al., 2013; Wang et al., 2018). This histo-
pathological classification has been amended by the etiological classifica-
tion based on the associated (mutated) gene since the underlying causal
defects leading to CMs are Mendelian gene mutations (Claeys, 2020).
One of the latest identified disease-associated genes for CMs pre-
senting with overlapping clinical and histopathological features of core,
centronuclear, myofibrillar, and nemaline myopathies is the pyridine
nucleotide-disulfide oxidoreductase domain 1 (PYROXD1) gene (O'Grady
et al., 2016). The first publication of the phenotypes associated with path-
ogenic variants in PYROXD1 revealed an early-onset myopathic disease
with slow progression but also with signs of dystrophy in the muscle biop-
sies and myofibrillar alterations, mostly in families with Turkish origin
(O'Grady et al., 2016). Subsequent publications revealed PYROXD1 vari-
ants causing congenital myopathy but, interestingly, showing that patients
with an adult-onset muscular dystrophy phenotype as well (Lornage
et al., 2019; O'Grady et al., 2016; Saha et al., 2018; Sainio et al., 2019) are
having the same variant c.464A>G, p.Asn155Ser in a homozygous or com-
pound heterozygous state. Thus, the genotype–phenotype correlation of
PYROXD1-related primary muscle disease has not been well understood
because of the wide clinical spectrum of reported phenotypes.
In this report, we describe three Turkish cases presenting with an
early-onset and slow progression of muscle weakness. We performed
detailed clinical, genetic, and histopathological investigation. To
enhance our understanding of the PYROXD1-related myopathies, we
performed a systematic review of all published cases. These findings
prompted us to investigate if this particular variant could be a founder
mutation in families of Turkish descent. Indeed, haplotype analyses
confirmed that c.464A>G is a founder mutation in the Turkish
population.
2 | MATERIAL AND METHODS
2.1 | Histopathology studies
The muscle biopsy at the age of 12 years from Patient 1 (Yis et al., 2018)
and at the age of 8 years from Patient 3 was processed with standard
techniques and was analyzed histologically as described elsewhere
(Dubowitz & Sewry, 2013). Additionally, immunohistochemistry was per-
formed using myotilin antibody (Novocastra, UK, NCL-myotilin), and the
neonatal myosin heavy chain antibody (Novocastra, UK, NCL-MHCn)
was used for the identification of immature fibers (further details in Sup-
plementary Data [Appendix S1]).
2.2 | Genomic analyses
For Patient 3, initially we performed Mendeliome sequencing with Illumina
TruSight One (Illumina, San Diego, California, USA) on an Illumina HiSeq
2000 (Wunderlich et al., 2018), but no convincing pathogenic variant could
be identified. Later, we used the Agilent SureSelect V6 enrichment kit for
whole-exome sequencing (WES) on a HiSeq 4000 sequencer (Illumina,
USA) for Patients 1 and 3 with a paired-end 76-bp sequencing protocol
according to the manufacturer's recommendations (Wang et al., 2018).
Data analysis for both patients was performed with the in-house software
Varbank of the Cologne Center for Genomics (Dafsari et al., 2019; Per-
gande et al., 2020). In brief, technical details on data analysis and variant
filtering are given in the Supplementary Data (Appendix S1). Variants were
filtered for rare (minor allele frequency 0.1%) homozygous variants (allele
read frequency of 75%–100%) in accordance with the expected autoso-
mal recessive mode of inheritance and the known consanguineous back-
ground for both patients, as well as for compound heterozygous
constellations for both patients. Variants were classified based on their
potential pathogenicity (Supplementary data [Appendix S1]). Sanger
sequencing was used for the validation of candidate variants in PYROXD1
and TTN (data not shown) as well as cosegregation analysis.
2.3 | Systematic literature survey and statistical
analyses
We have performed descriptive statistical analysis for all PYROXD1
patients published in PUBMED (https://www.ncbi.nlm.nih.gov/pubmed/)
including the three patients reported here (Lornage et al., 2019; O'Grady
et al., 2016; Saha et al., 2018; Sainio et al., 2019) (further details are given
on methods in Supplementary data [Appendix S1]).
2.4 | Haplotype analysis
For haplotype analysis of the mutation NM_024854.3:c.464A>G (GRCh37/
hg19) on chromosome 12 at cytoband p12.1 (chr12:21452130A>G), micro-
satellite markers were genotyped by PCR with fluorescently labeled primers
(Supplementary Table 6–8) and subsequent fragment analysis performed
on an ABI 3730XL sequencer (Applied Biosystems). GeneMarker software
(Gene Marker Version 1.51) was used for allele calling. Single nucleotide
polymorphisms (SNPs) were genotyped by Sanger sequencing of all family
members (Supplementary Figure 2–6). For both families (Figure 3), haplo-
types were reconstructed manually and visualized with HaploPainter ver-
sion 1 (further information is given in Supplementary data [Appendix S1]).
3 | RESULTS
3.1 | Clinical description
Patient 1 was a 17-year-old female and the sixth child of Turkish con-
sanguineous parents (Table 1). The sibling of Patient 1, who is the































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































DAIMAGÜLER ET AL. 1681
oldest child, was a 38-year-old female (Patient 2), still alive and walk-
ing with support, presenting same phenotype as her sister according
to the reporting parents. The fifth child and brother of Patients 1 and
2 (Figure 2(a)-1: 1:II-5) had died at the age of 14 years (y) due to car-
diomyopathy. No material of the brother was available for any geno-
mic analyses. Patient 1, the youngest of six children, had normal
perinatal history, and motor milestones were normal. Clinical examina-
tion at the age of 12 years showed a generalized reduction in the
muscle bulk, symmetrical more proximal, but also showed distal mus-
cle weakness with Gowers' sign (Supplementary: Video 1), neck weak-
ness and scapular winging. The creatine kinase (CK) value was normal:
75 IU/L (0–171). The deep tendon reflexes (biceps, triceps, patella,
and Achilles) were absent. She started walking at 12 months of age;
the first signs of muscle weakness were observed at the age of
6 years. There was mild joint laxity in the upper extremities, and no
contractures were observed. She was still ambulant now at the age of
18 years. Furthermore, the patient had facial weakness, nasal speech,
and mild difficulties in swallowing, without ophthalmoplegia. Nerve
conduction velocities and amplitudes were normal in the left median,
ulnar, and peroneal motor nerves. Sensory nerve conduction velocities
and amplitudes of left median, ulnar, and sural nerve were also normal.
Electromyography of left tibialis anterior, left quadriceps femoris, and
right biceps muscles revealed myopathic motor unit potentials. No
signs of cardiac dysfunction have been observed until now. Her cogni-
tive and speech development was normal according to her age.
Patient 3 was an 8-year-old boy who was the first and only off-
spring of consanguineous (first-degree cousins) Turkish parents
(Figure 1(a)-(c)). He was diagnosed at the age of 8 years with congeni-
tal myopathy with normal CK level (41 IU/L). The patient had difficul-
ties in walking due to his falls, and he could only climb the stairs with
help. Clinical examination at the age of 7 years showed a myopathic
expression in a long and narrow face, large ears (Figure 1(a)), a thin
hand, and long flexible fingers (Figure 1(b),(c)). The total muscle mass
was decreased, but the cranial nerve examination was normal at that
time. In addition, he had facial weakness, nasal speech, and difficulties
with swallowing. The patient had neck muscle weakness and lower
and upper proximal weakness. Myotonic reactions could not be
elicited, and the cranial magnetic resonance imaging was normal. The
diagnostic molecular genetic testing for fragile X syndrome was nega-
tive. At the age of 8 years, the nerve conduction velocity showed axo-
nal neuropathy changes that were interpreted as polyneuropathy. He
did not show any clinical signs of cardiomyopathy.
3.2 | Muscle biopsy findings
A muscle biopsy (Table 2) was carried out for both patients (Figure 1
(d)-(h), Supplementary Figure 1(a)-(d)). An incisional biopsy from the
deltoid muscle of patient 1 (Figure 1(d)-(h)) showed degenerative
myopathic changes in H&E staining including fiber size variability,
multiple internalized nuclei, atrophic fibers, and increased fibrous con-
nective tissue (Figure 1(d)). NADH-TR staining showed cores in the
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modified trichrome (Figure 1(f)). Neonatal myosin staining showed
immature and regenerating fibers (Figure 1(g)). There were a few cen-
tral inclusions expressing myotilin (Figure 1(h)). Type 2 myofibers were
slightly decreased in the fast and slow myosin heavy chain staining.
All the other immunohistochemical analysis showed no abnormalities
(Supplementary Data [Appendix S1]). Muscle biopsy results indicated
a noninflammatory myopathy.
Patient 3 had a muscle biopsy (Supplementary Figure 1(a)–(d))
performed at the age of 7 years, which showed dystrophic changes.
H&E staining (Supplementary Figure 1(a),(b)) represented the presence
of abundant small rounded muscle fibers with centrally located nuclei
and a noticeable increment of fat tissue in the sections. The patients'
muscle biopsy clearly showed dystrophic changes with increased con-
nective tissues within endo- and perimysium and irregular desmin
aggregates in sarcoplasm (Supplementary Figure 1(c),(d)).
3.3 | Genomic and haplotype results
For Patient 1 (Figure 2(a)), WES analysis revealed a homozygous vari-
ant in PYROXD1 (NM_024854.3), c.464A>G causing p.Asn155Ser
(Figure 2(c),(d)). The variant had already been published as pathogenic
(O'Grady et al., 2016) and reported in the Exome Variant Server
(seven heterozygous cases), gnomAD (AF:0.00004624), the general
F IGURE 1 Patient phenotype and muscle biopsy. (a)-(c) Phenotype of patient 3: (a) Long myopathic face and facial weakness. (b) Muscle
atrophy of shoulder and neck muscles (c) Distal joint laxity. (d)-(i) Muscle Biopsy for patient 1: (d) Muscle biopsy shows the variation in fiber size,
multiple internalized nuclei, and increased fibrous connective tissue (HE ×400), (e) Conspicuous central core formations and myofibrillar
irregularity (NADH-TR ×400), (f) Note the increased number of central nuclei (Modified Trichrome ×400), (g) Immature regenerating fibers
expressing neonatal myosin (DAB ×400), (h) There are a few central inclusions highly immunoreactive to myotillin. (Scale bars = 25 μm) (i) Patient
3 muscle biopsy shows severe fatty infiltration, variation in fiber size with a predominance of atrophic fibers and internal nuclei in most fibers. An
increase in endomysial connective tissue is also present (H&E stain). More stainings of Patient 3 are shown in Supplementary Figure 1 [Color
figure can be viewed at wileyonlinelibrary.com]
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minor allele frequency without any homozygous cases, and in ClinVar
(Supplementary Table 2–3). This variant was classified as pathogenic
by the ACMG standards and criteria guidelines (Richards et al., 2015),
and it is conserved through evolution (Figure 2(d)). In addition, our fil-
tering results revealed different TTN variants in Patient 1 (Supplemen-
tary Table 3), which were excluded by lack of cosegregation (data not
shown).
Mendeliome sequencing based on the gene list of 2013
(Wunderlich et al., 2018) did not reveal any pathogenic variants
because PYROXD1 was not included in the panel. WES for Patient
3 (Figure 2(b)) revealed compound heterozygous mutations in
PYROXD1 (Figure 2(c),(d)); in addition to mutation c.464A>G, p.
Asn155Ser, a novel frameshift variant c.329_332delTCTG, p.Leu112-
Valfs*8 was found (Supplementary Table 3), which was not reported
in the Exome Variant Server, gnomAD, Great Middle Eastern database
(GME), Iranome, ClinVar and 1000 genomes databases
(Supplementary Tables 4 and 5). We classified this variant as likely
pathogenic (Richards et al., 2015).
Haplotype analysis around the c.464A>G, p.Asn155Ser (chr12:
21605064A>G) variant (Supplementary Table 9–10) was performed
for both families of Turkish origin. We proved that both families share
a haplotype of 282,729 bp (Figure 3 Family 1–2, red boxes). In Family
F IGURE 2 Genomic analysis and protein domain scheme. (a),(b) Pedigrees and cosegregation of family 1 (a) with patient 1 (II:6) and patient
2 (II:1) and family 2 (b) with patient 3 (II:1). Patient 1 (II:6) clearly shows a homozygous variant (red arrow) in PYROXD1 (c.464A>G, p.Asn155Ser),
and her older sister is affected and has the same variant. Both parents are heterozygous for this variant. Patient 3 has two variants in PYROXD1,
c.464A>G, p.Asn155Ser and c.329_332del, p.Leu112Valfs*8. The father (c.464A>G, p.Asn155Ser) and the mother (c.329_332del, p.
Leu112Valfs*8) of patient 3 are heterozygous for one of the two variants in PYROXD1. (c) Protein structure of PYROXD1, which has two
important domains, the nuclear-cytoplasmic pyridine nucleotide-disulfide reductase (PNDR) domain (shown in purple) and the NADH-dependent
nitrite reductase (NADH) domain (shown in rose). The most common variant in PYROXD1 is p.Asn155Ser (blue); other found missense mutations
are p.Tyr354Cys (purple) and p.Gln372His (green). The here reported novel frameshift mutation is shown in red. Three of the variants are located
in the PNDR domain of PYROXD1. (d) The variant p.Asn155Ser is conserved through evolution in different species: 1. Homo sapiens
(NP_079130.2), 2. P. troglodytes (XP_520786), 3. Macaca mulatta (XP_001098386.1), 4. Bos taurus (NP_001098804), 5. Mus musculus
(NP_898988), 6. R. rattus (NP_001004234), 7. Gallus gallus (XP_001264205), 7. Danio rerio (NP_957057.1), and 8. Xenopus tropicalis
(NP_001120558.1). For our alignment, we used NCBI FASTA files of the different species and add this to Jalview alignment with MuscleWS
using service hosted at http://www.compbio.dundee.ac.uk/jabaws (MuscleWS version 3.8.31). Afterward, secondary structure analysis on
alignment was done by using JPred secondary structure analysis in Jalview, seen in here as JNetHMM. The helices are marked as red tubes and
the ß-sheets as green arrows in the alignment. At the end, we used a color scheme, here Blossum62, which uses white for gaps, dark purple for
residues matches the consensus sequence residue, and light purple for not matching to consensus residue, but the second residue does. The
consensus is also displayed in yellow from the lowest (0) to the highest one (10) [Color figure can be viewed at wileyonlinelibrary.com]
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1, we found the same haplotype heterozygous in both parents and
homozygous in the two affected siblings (Patients 1 and 2 in Figure 3,
Family 1). No DNA material of the other three healthy siblings was
available (healthy siblings are not shown in Figure 3 and Supplemen-
tary Figure 2–6). In the second family, Patient 3 has a second muta-
tion in PYROXD1 that causes a frameshift by a deletion (Figure 3,
Family 2). Clearly, we have been able to show the heterozygous hap-
lotype together with the missense variant in this family too (Figure 3,
red boxes), except the mother. These findings proved the variant
c.464A>G as a Turkish origin founder mutation. Comparing the geno-
mic data including SNVs of our two patients with the published haplo-
type region in three Turkish families in the publication of O'Grady
(O'Grady et al., 2016) revealed the same homozygous region in all
Turkish families. Furthermore, we discovered a larger homozygous
region in our patients by adding our microsatellites and SNP positions
to the already found homozygous region in the five families. Conclu-
sively, our analysis not only showed that c.464A>G is a founder muta-
tion in the Turkish population, but a shared homozygous region with
earlier published cases was also discovered here, indicating an
identity-by-descent of this mutation in the analyzed cases
(Supplementary Table 10).
3.4 | Statistical results of systematic literature
survey
The statistical analysis of the 23 included individuals shown in Table 3
(Lornage et al., 2019; O'Grady et al., 2016; Saha et al., 2018; Sainio
et al., 2019) revealed that the current median age of the patients by
the phenotypes is 15y, with age range from 7 to 22y for the early-
onset patients, and 65 year for the adult ones, with an age range from
26 to 82 year. It represents the current age by different age groups,
leading to a childhood–teenage group with an average age of
12.5 year (n = 7), adult age group with 31 year (n = 8), and an old age
group with 72 year (n = 5) as current age. The age of onset of the
patients, including all patients with and without the founder mutation
can be divided in three groups, starting with the early-onset patients
with an age range from neonatal up to 3 year resulting in an average
age onset of 1.5 year (n = 11). The second group, the childhood-onset
patients, has an age range from 4 to 10 year, resulting in an average
age of 7.4 year (n = 10), and the adult-onset patients demonstrate an
average age of onset of 32 year (n = 6). It was found that the youngest
age of onset occurred during the neonatal period and the oldest one
at 50 year of age, and both the cases are carrying founder mutation.
F IGURE 3 Haplotypes of family 1 and family 2. Representation of the haplotypes (GRCh37/hg19) determined for individuals with the
NM_024854.3:c.464A > G (12:21452130), variant at chromosome region 12p12.1. In Figure 3, both families' haplotypes, family 1 and family
2, were presented. For Family 1, we only showed the two female siblings (II:1 and II:2) and the deceased brother, and not included the healthy
siblings, because DNA was not available for genotyping. Haplotypes were reconstructed manually from the genotypes of following markers: IAPP
(12:21373538 A > G) (SNV); D12S1654 (STR); SCM3 (12:21583220–21,583,464) (STR); rs7957200 (SNV); rs2058464 (SNV); rs11046076 (SNV);
rs10161132 (SNV); rs2417991 (SNV); SCM4 (12:21661778–21,661,981) (STR); and ABCC9, (12:21852069 T > G) (SNV), and were visualized by
the HaploPainter software. The first column shows the name of the markers, and the second column shows the allelic position on chromosome
12. Each number on haplotypes represents different alleles for a microsatellite marker, and the letters represent different alleles for each SNV.
The NM_024854.3:c.329_332delTCTG (12: 21602540_21602543delTCTG) is the second compound heterozygous mutation in Family 2; the “+”
indicates the deletion and the”-“indicates the wt allele without deletion. The shared founder haplotype for PYROXD1 c.464A > G between the
individuals is marked with a red box. The analysis of the two families revealed 231.492 bp homozygous region in patients from the marker
D12S1654 (12:21569340) to the ABCC9 SNV [Color figure can be viewed at wileyonlinelibrary.com]





















































































































































































































































































































































































































































































































































































































































































































































































































































































































1686 DAIMAGÜLER ET AL.
The age of onset of the three patients without the founder mutation
was neonatal or in childhood. The percentage of the patients who are
homozygous for the founder mutation are 61% (n = 14), and 39% are
compound heterozygous (n = 9), with 26.1% (n = 6) of them having
the founder mutation. The founder mutation is the only one found in
homozygous state in all reported patients with PYROXD1.
The most common clinical features of PYROXD1-mutated patients
are facial weakness (52%), speech difficulties (56.5%), swallowing
difficulties (17.4%), ptosis (21.4%), and high CK levels (26%). Cardiac
involvement was only found in 17.4% of the patients, but half of the
patients have a respiratory insufficiency (43.8%). Signs of neuropathy
were reported in 47.8% of all reported PYROXD1 patients.
In total, 14 patients out of 23 had a described muscle biopsy
(60.8%) (Table 2). In Table 3, the statistical analysis revealed that the
patients can be divided into three groups by their age at biopsy,
starting with group (I) until the teenage age with a mean age at









Current median age of patients by phenotype in years (y)
(n = 23)
I. Early-onset (onset of disease until 6y): 15y (age range from 7 to 29y),
II. Adult-onset (onset of disease after 6y): 65y (age range from 26 to 82y)
Current mean age of patients by age-groups in years (y)
(n = 23)
I. Childhood-teenager (7-17y):12.5y (n = 7),
II. Adult age (21-46y): 31y (n = 8),
III. Old age (65-82y): 72y (n = 5)
Average age of onset in years (y) I. Early onset up to 3y:1.5y (n = 11),
II. Childhood onset (up to 10y):7.4y (n = 10),
III. Adult onset (up to age 50y):32y (n = 6)
Homozygous patients (c.464A > G, p.Asn155Ser) 61% (n = 14)
Compound heterozygous patients / of them with founder mutation 39% (n = 9) / 26.1% (n = 6)
CK elevated (range 340-1000 U/L) 26% (n = 6)
Cardiac involvement 17.4% (n = 4)
Facial weakness 52.2% (n = 12)
Swallowing difficulty 21.7% (n = 5)
Speech difficulty 52.2% (n = 12)
Ptosis 21.7% (n = 5)
Respiratory involvement 43.5% (n = 10)
Neuropathic signs 47.8% (n = 11)
Muscle biopsy 60.8% (14/23)
Average age at biopsy 22y (n = 12)
Average age at biopsy classified in 1. Until teenage age = 9.5y (n = 9),
2. Middle age = 37y (n = 1),





Thin filament accumulation 28.6%
Nemaline rods 42.6%
Fiber size variability 85.7%
Fatty replacement 71.4%
Increased fibrosis 71.4%
Overall muscle biopsy evaluation reported 79% myopathic, 21% dystrophic
Note: This overview shows the statistical analysis of the patients with general aspects (ethnicity and age), clinical factors including age of onset, cardiac
involvement, weakness and difficulties of patients, and biopsy results.
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9.5 year for 9/14 patients (65%), second group (II) only one patient at
the age of 37 year and the last, and third group (III) with a mean age
of 68 year including two of 14 patients. Most common features in the
muscle biopsy were fiber size variation (85.7%), internalized nuclei
(78.6%), central cores (71.4%), myofibrillar inclusions (64.3%), fatty
replacement (71.4%), and fibrosis (71.4%). The muscle biopsy changes
had been interpreted as myopathic for most of the patients, except
the Finnish patients, who were described as dystrophic.
4 | DISCUSSION
The genomic analysis of the three patients reported here led us to
PYROXD1 (Figure 2(a)-(d)). We proved that the PYROXD1 c.464A>G,
p.Asn155Ser variant is a founder mutation in the Turkish population,
although it was not reported in the GME Variome. The gnomAD data-
base showed six heterozygous individuals in the healthy Finnish and
another six heterozygous in the European population harboring the
founder mutation. Unfortunately, no Turkish genome database exists.
Our own analyses revealed that the three cases reported here were
obtained from the 807 exome-sequenced patients, of which 287 were
Turkish-origin patients, revealing an allele frequency of 0.0052
(3/574) for the Turkish population calculated from our in-house data-
base. In gnomAD 10.824, Finnish patients have been sequenced, and
only six heterozygous individuals were found to harbor the founder
mutation, which gives an AF of 0.00055 for the Finnish population.
Our haplotype analysis showed a shared haplotype of 231,492 bp
spanning the variant c.464A>G, (chr12:21605064A>G) in both fami-
lies (Figure 3, Family 1 and 2, red boxes). A homozygous haplotype
around this variant c.464A>G (chr12:21605064A>G) was also
reported by O'Grady et al. in three Turkish families (O'Grady
et al., 2016). We compared the genomic data of all five Turkish fami-
lies (Supplementary Table 10), which revealed the same shared homo-
zygous region of haplotypes (348,622 bp), supporting our findings. A
deeper understanding of the spatial patterns of relatedness in subpop-
ulations could be gained by using haplotype analysis on reported PYR-
OXD1 patients with the c.464A>G mutation.
The founder mutation has a predicted destabilizing effect on PYR-
OXD1 by the amino acid substitution (Supplementary Figure 7A-C).
The used “DynaMut” molecular dynamics prediction (described in
Supplementary Data [Appendix S1]) showed that the asparagine at
position 155 (Supplementary Figure 7(b), (c)-in green) is located in the
α-helix (H6) of PYROXD1. Asparagine maintains the α-helical struc-
ture by several bonds (gray-dashed line) and a main binding to trypto-
phan (Supplementary Figure 7(b), (c)–green-dashed line) and the red-
dashed H-bonds with the peptide backbone. The prediction analysis
showed that replacing asparagine by serine which has an OH-group
instead of a carboxamide group has a destabilizing effect on the PYR-
OXD1 structure (Supplementary Figure 7(d), (e) in green).
All published patients are listed in Table 1 and can be divided into
(1) individuals with an early-onset phenotype, including facial weak-
ness, nasal speech, and swallowing difficulties, but still ambulant with
help and (2) individuals with an adult phenotype alive up to 80 years
of age, showing first symptoms in the 40s or even 50s with no cardiac
involvement, normal CK levels, and no facial weakness (O'Grady
et al., 2016; Saha et al., 2018). The founder mutation c.464A>G has
been reported to cause two different phenotypes, (i) and (ii), and it
was observed either in homozygous (14/23, 61%) or compound het-
erozygous (6/23, 26%) state.
The Turkish founder mutation was reported in total in 14/23
(61%) patients in homozygous state; six of them have been Turkish-
origin patients. All of the Turkish-origin patients were consanguine-
ous, showed high CK levels, facial weakness (6/6), and speech difficul-
ties (6/6). The Turkish patients also had mild ptosis (4/6), one with
respiratory insufficiency (1/6) and nearly all having neuropathy signs
(5/6). The non-Turkish patients showed less frequent facial weakness
(1/8), speech difficulties (2/8), and ptosis (1/8), but respiratory insuffi-
ciency was found in 50% of this subgroup of patients (4/8). The age
of onset in the homozygous group of all populations suggests the divi-
sion in two groups, one early to childhood, from 2 to 10 years of age,
including the Turkish origin patients, and the second group with an
older age of onset from 30 to 50 years of age, including mostly Finn-
ish and Persian–Jewish patients.
Only four patients in the cohort were reported with cardiomyopa-
thy and, oddly, three of them having siblings (Table 1, patients: 1b, 2b,
and 9b) without cardiac involvement. Each sibling pair has the same
genotype. The most likely reason for these discordant cardiac pheno-
types could be secondary genetic variants in other genes (genetic
modifiers). Cases reported without the founder mutation are all com-
pound heterozygous (3/23) (Table 1). Two of them are European sib-
lings with an essential splice-site mutation (O'Grady et al., 2016), and
one of them has a functional deep intronic mutation and is wheelchair
bound since the age of 12 year (Lornage et al., 2019). Conclusively,
the founder mutation has been the only reported homozygous muta-
tion in PYROXD1 patients (Table 1, Table 3).
The function of PYROXD1 is still unknown, but it has been localized
to the nucleus and sarcomeres of human muscles and zebra fish (pyroxd1)
myofibers (O'Grady et al., 2016). PYROXD1 is a class I pyridine
nucleotide-disulfide oxidoreductase (PNDR), predicted to have a flavin
adenine dinucleotide (FAD) binding site (O'Grady et al., 2016). Three dif-
ferent isoforms of PYROXD1 have been described (Supplementary
Figure 8 for isoform 1 and 2); besides the longest isoform (isoform
1, NM_024854.5, ENST00000240651.14, Figure 2(C)), two other
isoforms with a shorter N-terminus are existing. Isoform
2 (NM_001350912.1, ENST00000538582.5) has same domains as iso-
form 1 and isoform 3 (NM_001350913.2, data not shown) containing
only one domain, the PNDR domain. Isoform 1 is widely expressed
among all tissues in comparison with isoform 2, which shows no expres-
sion in skeletal muscle (Supplementary Figure 8, red box and arrow).
Complementation assays with PYROXD1 in yeast lacking glutathione
reductase have shown its reductase activity and have also shown that
the glutathione reductase activity was impaired by the missense mutation
c.464A > G, p.Asn155Ser and could be rescued by human wt PYROXD1
(O'Grady et al., 2016). Glutathione reductase has an important role for
the survival of cells against oxidative stress induced by, for example, reac-
tive oxygen species (ROS) (Wu & Batist, 2013).
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Recently, PYROXD2 was reported as a protein localized in the inner
membrane of the mitochondria (T. Wang et al., 2019). The knockout of
PYROXD2 led to increased levels of mitochondrial ROS (mtROS) (T. Wang
et al., 2019), which is known to cause cellular damage and also to mis-
folding of mitochondrial proteins (Chandel, Schumacker, & Arch, 2001),
indicating that PYROXD2 is a regulator of the mitochondrial activity and
regulates mtROS levels. No functional association between PYROXD1
and PYROXD2 was reported yet, but the function of PYROXD2 as a regu-
lator of mtROS (Wang et al., 2019) and the fact that PYROXD1 rescued
the yeast glutathione reductase knockout in a complementation assay
(O'Grady et al., 2016) suggested that PYROXD1 could be involved in the
compensation of oxidative stress in other cellular compartments than
mitochondria. Furthermore, high levels of HSP70 and glutathione reduc-
tase in patients muscle tissue inWestern blot analysis suggested that PYR-
OXD1 could be also a regulator of autophagy (Lornage et al., 2019) and
ROS. PYROXD1 could be a specific regulator of the ROS in the nucleus
by its localization. Interestingly, used online tools predicted a nucleus local-
ization signal sequence for PYROXD1 from amino acid position 250–282,
which predicts a transport to the nucleus by importin-alpha
(Supplementary Figure 9), but PYROXD1 is also in the cytoplasm. Cores
were found in the muscle biopsy of PYROXD1 patients (Figure 1(e)), which
was also reported in loss-of-function mutations in SEPN1 patients muscle
fibers (Marino et al., 2015; Scoto et al., 2013), additionally with small focal
areas in the mitochondria (Arbogast & Ferreiro, 2010). SEPN1, also called
SELENON (Varone et al., 2019), belongs to the selenoproteome
(Arbogast & Ferreiro, 2010) characterized by selenocysteines with no clas-
sical FAD or NADH binding domains (Lescure, Gautheret, Carbon, &
Krol, 1999). Mutations found in the SELENON cause congenital core
myopathy phenotypes (Marino et al., 2015; Moghadaszadeh et al., 2001)
and are leading to alteration of the antioxidant systems (Arbogast
et al., 2009) and Ca2+ homeostasis (Marino et al., 2015) in muscles. Low
levels of ROS and NO are produced in a healthy muscle, important for the
excitation–contraction coupling and signal transduction. Higher levels of
both, ROS and NO after exercise could lead to oxidative and nitrosative
stress in the muscle, if not regulatory mechanism fail, leading to dysfunc-
tion or lethality of the myofibers. Arbogast et al., was the first to analyze
intracellular oxidant activity in human SELENON-mutated fibroblast and
myotubes and showed that they contained high levels of oxidized
sarcomeric protein in OxyBlot's. These findings indicate a specific disease
mechanism of ROS-related myopathies and SELENON deficiencies
(Arbogast et al., 2009). As we know that PYROXD1 is a regulator of ROS
in the muscle, like SELENON (Arbogast et al., 2009), we hypothesize that
hyperoxidation of contractile muscle proteins could be a specific disease
mechanism for PYROXD1-related myopathies. This could be confirmed by
utilizing OxyBlot' kit from patients' muscle biopsies. Further research in
patient material and in murine models would be required to understand
the biological role of PYROXD1 against oxidative stress in skeletal muscle.
5 | CONCLUSION
In this study, we report three patients with an early-onset myopathy
due to PYROXD1 mutations. Our in-depth haplotype analyses proved
that the c.464A>G, p.Asn155Ser substitution is a founder mutation in
the Turkish population. Our systematic literature review revealed that
the PYROXD1 missense variant c.464A>G, p.Asn155Ser is the only
homozygous PYROXD1 mutation reported so far and may cause an
early- or an adult-onset phenotype, irrespective of if its occurrence
either in the homozygous or compound heterozygous state. Cardiac
involvement was rare. CK levels in PYROXD1-related myopathies
were usually below 1000 U/L.
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